<DOC>
	<DOCNO>NCT00123292</DOCNO>
	<brief_summary>The purpose trial evaluate safety efficacy microplasmin administration patient acute peripheral arterial occlusion .</brief_summary>
	<brief_title>Intra-arterial Microplasmin Administration Patients With Acute Peripheral Arterial Occlusion</brief_title>
	<detailed_description>This clinical trial design open-label , dose-escalating , single-centre trial weight-adjusted dose regimen microplasmin administer intra-arterially infusion patient acute peripheral arterial occlusion . Patients meet inclusion criterion none exclusion criterion administer study drug 4 hour . Different dose regimen evaluate ascending-dose fashion ; infusion administer 4 hour .</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Fibrinolysin</mesh_term>
	<criteria>Patients present within 14 day onset acute thrombotic embolic arterial occlusion lower extremity ( native vessel bypass graft ) . Complete occlusion infrarenal vessel bypass graft , determine angiography . Lower extremity ischemia grade SVS/ISCS ( Society Vascular Surgery/ International Society Cardiovascular Surgery ) class I II ( b ) . Negative urine pregnancy test ( pregnancy test require female childbearing potential use accepted method contraception ) . Profound ischemia permanent motor paresis sensory loss ( ischemic process deem irreversible , i.e . class III ) . Occlusion penetrable infusion guide wire . Known suspected allergy contrast agent heparin sodium . Active bleed know hemorrhagic diathesis . Stroke previous 6 month transient ischemic attack previous 2 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>arterial occlusion</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>Acute Peripheral Arterial Occlusion</keyword>
</DOC>